XML 72 R61.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Collaborative and Other Relationships (Details) |  |  | 3 Months Ended |
--- | --- | --- | --- | ---
Nov. 03, 2023 USD ($) payment | Nov. 05, 2019 USD ($) | Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Nov. 30, 2023
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Revenues |  |  | $ 92,761,000 | $ 68,778,000 |
Torii Pharmaceutical Co. |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Revenues |  | $ 22,000,000 |  |  |
Potential milestone payments receivable if regulatory approval before specified date |  | $ 15,000,000 |  |  |
Maximum customary reduction on royalty rate |  | 50.00% |  |  |
Torii Pharmaceutical Co. | Minimum |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Royalty rate if maintains sakigake designation |  | 20.00% |  |  |
Royalty rate |  |  |  |  | 20.00%
Torii Pharmaceutical Co. | Maximum |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Royalty rate if maintains sakigake designation |  | 40.00% |  |  |
Royalty rate |  |  |  |  | 80.00%
Clearside Biomedical, Inc. |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Upfront payment | $ 5,000,000 |  |  |  |
Number of milestone payments | payment | 3 |  |  |  |
Number of royalties tiers | payment | 3 |  |  |  |
Clearside Biomedical, Inc. | Annual Net Sales Of $2 Million |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Annual global net sales | $ 2,000,000,000 |  |  |  |
Clearside Biomedical, Inc. | Annual Net Sales Greater Than $1.5 Million |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Annual global net sales | 1,500,000,000 |  |  |  |
Clearside Biomedical, Inc. | Maximum |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |
Potential milestone payment | 30,000,000 |  |  |  |
Potential payment if milestone reached | $ 47,500,000 |  |  |  |

X
- Definition License Agreement, Annual Global Net Sales + References No definition available. + Details
Name: | bcrx_LicenseAgreementAnnualGlobalNetSales
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Number of Milestone Payments + References No definition available. + Details
Name: | bcrx_LicenseAgreementNumberOfMilestonePayments
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Royalty Payment, Number of Tiers + References No definition available. + Details
Name: | bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Upfront Payment + References No definition available. + Details
Name: | bcrx_LicenseAgreementUpfrontPayment
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The maximum percentage of customary reductions allowed on royalty rate. + References No definition available. + Details
Name: | bcrx_MaximumCustomaryReductionOnRoyaltyRate
Namespace Prefix: | bcrx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential Milestone Payments Payable + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsPayable
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Milestone Payments Payable If Regulatory Approval Before Milestone + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of potential milestone payments receivable if regulatory approval is granted. + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalty Rate + References No definition available. + Details
Name: | bcrx_RoyaltyRate
Namespace Prefix: | bcrx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review. + References No definition available. + Details
Name: | bcrx_RoyaltyRateIfMaintainsSakigakeDesignation
Namespace Prefix: | bcrx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOf2MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesGreaterThan15MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |